bacteroides fragilis BF839 + lactobacillus rhamnosus TT-628

This is a combination probiotic product containing two specific bacterial strains: *Bacteroides fragilis* BF839 and *Lactobacillus rhamnosus* TT-628. **Bacteroides fragilis* BF839** is a gram-negative anaerobic bacillus isolated from healthy human gut flora, widely used in China as a next-generation probiotic. It has demonstrated benefits in improving gut microbiota dysbiosis-related symptoms such as constipation and diarrhea, reducing chemotherapy-induced gastrointestinal toxicity and myelosuppression, ameliorating graft-versus-host disease (GVHD), and enhancing anti-tumor immunity—particularly by increasing CD8+ T cell infiltration via the cGAS-STING pathway, which may improve responses to immune checkpoint inhibitors in cancer therapy[1][2][4][5]. **Lactobacillus rhamnosus* TT-628** is a strain of lactic acid bacteria known for its ability to support digestive health by strengthening the intestinal barrier, modulating immune responses, inhibiting pathogenic bacteria colonization, and promoting beneficial short-chain fatty acid production[6][8]. This species has been studied for relief of irritable bowel syndrome (IBS) symptoms and restoration of healthy gut microbiota after antibiotic use or gastrointestinal illness. The combination aims to synergistically restore microbial balance in the gut, enhance mucosal immunity, reduce inflammation, protect against gastrointestinal side effects from medical treatments (such as chemotherapy), and potentially improve outcomes in diseases linked to dysbiosis or immune dysfunction.

Other names

bacteroides fragilis BF839 + lactobacillus rhamnosus TT-628